Subdural Hematoma and Oral Anticoagulation: A Therapeutic Dilemma from the Neurosurgical Point of View

 

 Buy Article Permissions and Reprints

Abstract

Background Oral anticoagulation is a common prophylactic therapy for several diseases with a high thromboembolic risk. Such medication harbors a possible hemorrhage risk, with a special risk for subdural hematoma (SDH). The safety and efficacy of resumption of oral anticoagulation versus long-term discontinuation has not been fully clarified in patients who experienced SDH while under treatment with oral anticoagulation.

Material and Methods We investigated the outcome of 49 patients who were identified retrospectively to have a SDH while receiving oral anticoagulation.

Results Most bleeding occurred while patients were within the recommended therapeutic window for oral anticoagulation. Mortality was 15%. The event-free survival probability was higher in the group of patients with reinstitution of phenprocoumon therapy than in the group without. Over a median follow-up of 32 months, thromboembolic events occurred in 4 of 23 patients without oral anticoagulation versus in none of 15 patients with phenprocoumon; hemorrhagic complications occurred in 1 in 23 versus 3 in 15 patients.

Conclusions Reinstitution of oral anticoagulation with phenprocoumon after previous SDH appears to have an acceptable risk for hemorrhagic complications. Decision making might consider case-by-case differences. To establish specific guidelines, prospective large cohort studies are needed.

• References

• 1 Taborski U, Müller-Berghaus G. State-of-the-art patient self-management for control of oral anticoagulation. Semin Thromb Hemost 1999; 25 (1) 43-47
  Article in Thieme ConnectPubMedGoogle Scholar
• 2 Connolly BJ, Pearce LA, Hart RG. Vitamin K antagonists and risk of subdural hematoma: meta-analysis of randomized clinical trials. Stroke 2014; 45 (6) 1672-1678
  CrossrefPubMedGoogle Scholar
• 3 Hylek EM. Complications of oral anticoagulant therapy: bleeding and nonbleeding, rates and risk factors. Semin Vasc Med 2003; 3 (3) 271-278
  Article in Thieme ConnectPubMedGoogle Scholar
• 4 Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995; 26 (8) 1471-1477
  CrossrefPubMedGoogle Scholar
• 5 Bertram M, Bonsanto M, Hacke W, Schwab S. Managing the therapeutic dilemma: patients with spontaneous intracerebral hemorrhage and urgent need for anticoagulation. J Neurol 2000; 247 (3) 209-214
  CrossrefPubMedGoogle Scholar
• 6 Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral hemorrhage. N Engl J Med 2001; 344 (19) 1450-1460
  CrossrefPubMedGoogle Scholar
• 7 Claassen DO, Kazemi N, Zubkov AY, Wijdicks EF, Rabinstein AA. Restarting anticoagulation therapy after warfarin-associated intracerebral hemorrhage. Arch Neurol 2008; 65 (10) 1313-1318
  PubMedGoogle Scholar
• 8 Mattle H, Kohler S, Huber P, Rohner M, Steinsiepe KF. Anticoagulation-related intracranial extracerebral haemorrhage. J Neurol Neurosurg Psychiatry 1989; 52 (7) 829-837
  CrossrefPubMedGoogle Scholar
• 9 Rust T, Kiemer N, Erasmus A. Chronic subdural haematomas and anticoagulation or anti-thrombotic therapy. J Clin Neurosci 2006; 13 (8) 823-827
  CrossrefPubMedGoogle Scholar
• 10 Duff IF, Shull WH. Fatal hemorrhage in dicumarol poisoning; with report of necropsy. J Am Med Assoc 1949; 139 (12) 762-766
  CrossrefPubMedGoogle Scholar
• 11 Palareti G, Leali N, Coccheri S , et al; Italian Study on Complications of Oral Anticoagulant Therapy. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348 (9025) 423-428
  CrossrefPubMedGoogle Scholar
• 12 Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105 (2) 91-99
  CrossrefPubMedGoogle Scholar
• 13 Van Der Veken J, Duerinck J, Buyl R, Van Rompaey K, Herregodts P, D'Haens J. Mini-craniotomy as the primary surgical intervention for the treatment of chronic subdural hematoma—a retrospective analysis. Acta Neurochir (Wien) 2014; 156 (5) 981-987
  CrossrefPubMedGoogle Scholar
• 14 Forster MT, Mathé AK, Senft C, Scharrer I, Seifert V, Gerlach R. The influence of preoperative anticoagulation on outcome and quality of life after surgical treatment of chronic subdural hematoma. J Clin Neurosci 2010; 17 (8) 975-979
  CrossrefPubMedGoogle Scholar
• 15 Snyder M, Renaudin J. Intracranial hemorrhage associated with anticoagulation therapy. Surg Neurol 1977; 7 (1) 31-34
  PubMedGoogle Scholar
• 16 Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004; 164 (8) 880-884
  CrossrefPubMedGoogle Scholar
• 17 Jeffree RL, Gordon DH, Sivasubramaniam R, Chapman A. Warfarin related intracranial haemorrhage: a case-controlled study of anticoagulation monitoring prior to spontaneous subdural or intracerebral haemorrhage. J Clin Neurosci 2009; 16 (7) 882-885
  CrossrefPubMedGoogle Scholar
• 18 Gallus AS, Baker RI, Chong BH, Ockelford PA, Street AM. Consensus guidelines for warfarin therapy. Recommendations from the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2000; 172 (12) 600-605
  PubMedGoogle Scholar
• 19 Wintzen AR, Tijssen JG. Subdural hematoma and oral anticoagulant therapy. Arch Neurol 1982; 39 (2) 69-72
  CrossrefPubMedGoogle Scholar
• 20 Rizos T, Jenetzky E, Herweh C, Unterberg A, Hacke W, Veltkamp R. Fast point-of-care coagulometer guided reversal of oral anticoagulation at the bedside hastens management of acute subdural hemorrhage. Neurocrit Care 2010; 13 (3) 321-325
  CrossrefPubMedGoogle Scholar
• 21 Moskopp D, Brassel F, Ries F. Intracranial and intraspinal hemorrhages in treatment with coumarin derivatives. Catamnesis of 63 cases between 1978 and 1986. [in German]. Klin Wochenschr 1987; 65 (16) 781-790
  CrossrefPubMedGoogle Scholar
• 22 Senft C, Schuster T, Forster MT, Seifert V, Gerlach R. Management and outcome of patients with acute traumatic subdural hematomas and pre-injury oral anticoagulation therapy. Neurol Res 2009; 31 (10) 1012-1018
  CrossrefPubMedGoogle Scholar
• 23 Weigel R, Schmiedek P, Krauss JK. Outcome of contemporary surgery for chronic subdural haematoma: evidence based review. J Neurol Neurosurg Psychiatry 2003; 74 (7) 937-943
  CrossrefPubMedGoogle Scholar
• 24 König SA, Schick U, Döhnert J, Goldammer A, Vitzthum HE. Coagulopathy and outcome in patients with chronic subdural haematoma. Acta Neurol Scand 2003; 107 (2) 110-116
  CrossrefPubMedGoogle Scholar
• 25 Quon JA, Thiel HW, Cassidy JD, Donat JR. Anticoagulant therapy and subdural hematoma formation. J Manipulative Physiol Ther 1990; 13 (1) 30-32
  PubMedGoogle Scholar
• 26 Hirsh J, Fuster V ; American Heart Association. Guide to anticoagulant therapy. Part 2: Oral anticoagulants. Circulation 1994; 89 (3) 1469-1480
  CrossrefPubMedGoogle Scholar
• 27 Diamond T, Gray WJ, Chee CP, Fannin TF. Subdural haematoma associated with long term oral anticoagulation. Br J Neurosurg 1988; 2 (3) 351-355
  CrossrefPubMedGoogle Scholar
• 28 Fihn SD, McDonell M, Martin D , et al; Warfarin Optimized Outpatient Follow-up Study Group. Risk factors for complications of chronic anticoagulation. A multicenter study. Ann Intern Med 1993; 118 (7) 511-520
  CrossrefPubMedGoogle Scholar
• 29 Franke CL, de Jonge J, van Swieten JC, Op de Coul AA, van Gijn J. Intracerebral hematomas during anticoagulant treatment. Stroke 1990; 21 (5) 726-730
  CrossrefPubMedGoogle Scholar
• 30 Phan TG, Koh M, Wijdicks EF. Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk. Arch Neurol 2000; 57 (12) 1710-1713
  CrossrefPubMedGoogle Scholar
• 31 Gorter JW. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology 1999; 53 (6) 1319-1327
  CrossrefPubMedGoogle Scholar
• 32 Butchart EG, Gohlke-Bärwolf C, Antunes MJ , et al; Working Groups on Valvular Heart Disease, Thrombosis, and Cardiac Rehabilitation and Exercise Physiology, European Society of Cardiology. Recommendations for the management of patients after heart valve surgery. Eur Heart J 2005; 26 (22) 2463-2471
  CrossrefPubMedGoogle Scholar
• 33 Amin AG, Ng J, Hsu W , et al. Postoperative anticoagulation in patients with mechanical heart valves following surgical treatment of subdural hematomas. Neurocrit Care 2013; 19 (1) 90-94
  CrossrefPubMedGoogle Scholar
• 34 Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briët E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333 (1) 11-17
  CrossrefPubMedGoogle Scholar
• 35 Chari A, Clemente Morgado T, Rigamonti D. Recommencement of anticoagulation in chronic subdural haematoma: a systematic review and meta-analysis. Br J Neurosurg 2014; 28 (1) 2-7
  CrossrefPubMedGoogle Scholar
• 36 Romualdi E, Micieli E, Ageno W, Squizzato A. Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage. A systematic review. Thromb Haemost 2009; 101 (2) 290-297
  PubMedGoogle Scholar
• 37 Yeon JY, Kong DS, Hong SC. Safety of early warfarin resumption following burr hole drainage for warfarin-associated subacute or chronic subdural hemorrhage. J Neurotrauma 2012; 29 (7) 1334-1341
  CrossrefPubMedGoogle Scholar
• 38 Kawamata T, Takeshita M, Kubo O, Izawa M, Kagawa M, Takakura K. Management of intracranial hemorrhage associated with anticoagulant therapy. Surg Neurol 1995; 44 (5) 438-442 ; discussion 443
  CrossrefPubMedGoogle Scholar
• 39 Aspegren OP, Åstrand R, Lundgren MI, Romner B. Anticoagulation therapy a risk factor for the development of chronic subdural hematoma. Clin Neurol Neurosurg 2013; 115 (7) 981-984
  CrossrefPubMedGoogle Scholar
• 40 El Ahmadieh TY, Aoun SG, Daou MR , et al. New-generation oral anticoagulants for the prevention of stroke: implications for neurosurgery. J Clin Neurosci 2013; 20 (10) 1350-1356
  CrossrefPubMedGoogle Scholar
• 41 Le Roux P, Pollack Jr CV, Milan M, Schaefer A. Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage. J Neurosurg 2014; 121 (Suppl): 1-20
  CrossrefPubMedGoogle Scholar
• 42 Broderick JP, Adams Jr HP, Barsan W , et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1999; 30 (4) 905-915
  CrossrefPubMedGoogle Scholar
• 43 Appelboam R, Thomas EO. Warfarin and intracranial haemorrhage. Blood Rev 2009; 23 (1) 1-9
  CrossrefPubMedGoogle Scholar
• 44 Thrift AG, McNeil JJ, Forbes A, Donnan GA ; Melbourne Risk Factor Study Group. Three important subgroups of hypertensive persons at greater risk of intracerebral hemorrhage. Hypertension 1998; 31 (6) 1223-1229
  CrossrefPubMedGoogle Scholar
• 45 Fountain RB, Holmes DR, Chandrasekaran K , et al. The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) trial. Am Heart J 2006; 151 (5) 956-961
  CrossrefPubMedGoogle Scholar
• 46 Holmes DR, Reddy VY, Turi ZG , et al; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomized non-inferiority trial. Lancet 2009; 374 (9689) 532-542
  PubMedGoogle Scholar